Journal
GU Oncology Now Journal
Advertisement
At the ASTRO 2022 meeting, several authors presented abstracts on postprostatectomy radiation that are worth reviewing.
Upfront cytoreductive nephrectomy for patients with MRCC with immune checkpoint inhibitors or targeted therapy is examined.
Dr. Daniel Tennenbaum interviews Dr. Catherine H. Marshall on trends in managing advanced and metastatic prostate cancer.
Dr. Yasser Ged describes his GU oncology career that has spanned over three continents.
The Uromigos: Live & Unplugged event incorporated presentations and discussions in the field of urologic malignancies.
A detail of the analgesic modalities available for treatment of patients undergoing minimally-invasive urologic surgery.
According to a recent study published in The Lancet Oncology, radiation may offer safety and long-term efficacy for RCC.
By administering immediate single-dose intravesical chemotherapy, there is a 15% absolute risk reduction in tumor recurrence.
ASTRO 2022 included several interesting articles about genitourinary cancers, including prostate cancer and bladder cancer.
Up to one-third of all UTUC patients present with variant histology, such as squamous or micropapillary features.
Stereotactic body radiotherapy can benefit RCC patients deemed unfit for surgical therapy.
1 of 4 will UTUC patients will have a variant histologic subtype such as squamous cell, micropapillary, or neuroendocrine.
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.
Robert Uzzo gives an overview of the RENAL score that he developed, plus his outlook on the future of renal characterization.
The history of robot-assisted laparoscopic & open radical prostatectomies are discussed with their outcomes and future uses.
A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed.
Bradley McGregor, MD gives an overview of his GU oncology career from his Air Force beginnings to his work at Dana-Farber.
Dr. Catherine H. Marshall is interviewed on the use and future of chemotherapy for the treatment of advanced prostate cancer.
A review of “A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers” from the CKCis.
A guide to hereditary RCCs and their syndromes, as well as the relevant recommended guidelines for diagnosis and management.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.